3BDO NEW
| Price | $62 | $98 | $217 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: 3BDO | CAS No.: 890405-51-3 |
| Purity: 97.12% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | 3BDO |
| Description | 3BDO is a new mTOR activator. 3BDO inhibits autophagy. |
| In vitro | Phosphorylation of RPS6KB1 and EIF4EBP1 is significantly increased by 3BDO with vector alone but suppressed with FKBP1A overexpression. Rapamycin fails to decrease the phosphorylation of MTOR and RPS6KB1 in the presence of 3BDO. 3BDO suppresses the increase in MAP1LC3B puncta induced by rapamycin and inhibits its effect in HUVECs. Phosphorylation of Ser residues is decreased in HUVECs treated with 10 μM rapamycin, and 60 μM 3BDO reverses this phosphorylation. These results demonstrate that 3BDO suppresses the increased MAP1LC3B puncta, MAP1LC3B-II levels, and decreased SQSTM1 protein levels induced by rapamycin. Additionally, 3BDO decreases FLJ11812 levels in HUVECs in a dose- and time-dependent manner, while overexpression of FLJ11812 reverses the inhibition of autophagy induced by 3BDO[1]. |
| In vivo | Immunofluorescence assay demonstrates that treatment with 3BDO enhances p-p70S6K levels while reducing ATG13 protein levels in the plaque endothelium of mice, without affecting the phosphorylation of mTOR's immediate downstream targets p70S6K and 4EBP1. Comparatively, in apoE-/- mice, 3BDO treatment notably inhibits endothelium autophagy and apoptosis, thereby offering protection against endothelial injury in atherosclerosis. Furthermore, 3BDO treatment contributes to the stabilization of established atherosclerotic lesions in apoE-/- mice and results in a significant reduction in the serum levels of IL-6 and IL-8. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 150 mg/mL (458.25 mM), Sonication is recommended. Ethanol : 20 mg/mL (61.1 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (12.22 mM), Sonication is recommended. |
| Keywords | mTOR | Mammalian target of Rapamycin | Inhibitor | inhibit | Autophagy | Apoptosis | 3BDO |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Tamoxifen | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Angiogenesis related Compound Library | Neuroprotective Compound Library | Anti-Prostate Cancer Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $62.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY